ライフサイエンスコーパス: heparin-induced thrombocytopenia

1 ed with a variety of diagnoses and suspected heparin-induced thrombocytopenia.

2 myocardium, near infrared spectroscopy, and heparin-induced thrombocytopenia.

3 agulation monitoring and a reduced incidence heparin-induced thrombocytopenia.

4 ial in the workup of patients with suspected heparin-induced thrombocytopenia.

5 ts with warfarin-associated VLG complicating heparin-induced thrombocytopenia.

6 atients with cancer-associated thrombosis or heparin-induced thrombocytopenia.

7 th an immune-mediated adverse drug reaction, heparin-induced thrombocytopenia.

8 ntibodies can induce the adverse drug effect heparin-induced thrombocytopenia.

9 a synthetic heparin with a reduced effect of heparin-induced thrombocytopenia.

10 thrombocytopenia in the clinical syndrome of heparin-induced thrombocytopenia.

11 bilateral adrenal hemorrhage associated with heparin-induced thrombocytopenia.

12 mpleted prospective clinical trial (HIT [for heparin-induced thrombocytopenia] 5801 study; n = 500) o

13 Patients were 960 patients with heparin-induced thrombocytopenia (767 argatroban-treated

14 The differential diagnosis (including heparin-induced thrombocytopenia), a plan for management

15 latelet factor 4 (PF4) to polyanions induces heparin-induced thrombocytopenia, a prothrombotic advers

16 but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill me

17 In the case of suspected or confirmed heparin-induced thrombocytopenia, an alternative anticoa

18 associated with platelet activation, such as heparin-induced thrombocytopenia and autoimmune thromboc

19 inical disease, such as platelet factor 4 in heparin-induced thrombocytopenia and beta(2)-glycoprotei

20 The frequencies of heparin-induced thrombocytopenia and catheter-related bl

21 iven by lower rates of pulmonary embolus and heparin-induced thrombocytopenia and corresponding lower

22 Prevalence of heparin-induced thrombocytopenia and heparin-induced thr

23 corporeal membrane oxygenator (prevalence of heparin-induced thrombocytopenia and heparin-induced thr

24 , particularly ischemic stroke, is common in heparin-induced thrombocytopenia and significantly incre

25 itself to venous thrombus in the setting of heparin-induced thrombocytopenia and subsequent arterial

26 ssue of Blood, Rollin et al demonstrate that heparin-induced thrombocytopenia and thrombosis (HIT) pa

27 (PF4)/heparin complexes are the hallmark of heparin-induced thrombocytopenia and thrombosis (HIT), b

28 Heparin-induced thrombocytopenia and thrombosis (HITT) i

29 al and cardiac ICU who were presumed to have heparin-induced thrombocytopenia and underwent antiplate

30 All cases confirmed known characteristics of heparin-induced thrombocytopenia and uniformly revealed

31 or flush through the lumen (flush failure), heparin-induced thrombocytopenia, and catheter-related b

32 gnosis of storage pool disease, diagnosis of heparin-induced thrombocytopenia, and measurement of the

33 he biology of PF4-heparin complex formation, heparin-induced thrombocytopenia antibody binding occurs

34 olded PF4-M2 state, strongly suggesting that heparin-induced thrombocytopenia antibody recognizes a l

35 An immunoglobulin G class "heparin-induced thrombocytopenia antibody" attaches to a

36 Acquired hypercoagulable disorders such as heparin-induced thrombocytopenia, antiphospholipid syndr

37 age autoimmune thrombotic disorders, such as heparin-induced thrombocytopenia, antiphospholipid syndr

38 bstructive pulmonary disease (COPD), type II heparin-induced thrombocytopenia, atrial fibrillation, p

39 e evaluation and management of patients with heparin-induced thrombocytopenia, but also the measures

40 Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor pati

41 rhage and insufficiency as a complication of heparin-induced thrombocytopenia, coupled with the catas

42 ight patients met the algorithm criteria for heparin-induced thrombocytopenia diagnosis and seven of

43 embrane oxygenator; had significantly higher heparin-induced thrombocytopenia enzyme-linked immunosor

44 hough still considered experimental, TPE for heparin-induced thrombocytopenia for urgent cardiac surg

45 Bilateral adrenal hemorrhage associated with heparin-induced thrombocytopenia has become an increasin

46 n thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT) and immune thromb

47 ents in understanding the pathophysiology of heparin-induced thrombocytopenia (HIT) and in applying t

48 mediated platelet activation is essential in heparin-induced thrombocytopenia (HIT) and other immune-

49 Heparin-induced thrombocytopenia (HIT) antibodies recogn

50 rin reexposure despite a history of previous heparin-induced thrombocytopenia (HIT) can be appropriat

51 planation why only a subset of patients with heparin-induced thrombocytopenia (HIT) develop clinicall

52 Current methods of treating heparin-induced thrombocytopenia (HIT) focus on treatmen

53 Thrombosis results in heparin-induced thrombocytopenia (HIT) from cellular act

54 Laboratory testing for heparin-induced thrombocytopenia (HIT) has important sho

55 exchange (TPE) has been advocated to remove heparin-induced thrombocytopenia (HIT) IgG antibodies be

56 Heparin-induced thrombocytopenia (HIT) is a life- and li

57 Heparin-induced thrombocytopenia (HIT) is a life-threate

58 Heparin-induced thrombocytopenia (HIT) is a major cause

59 Heparin-induced thrombocytopenia (HIT) is a potentially

60 Heparin-induced thrombocytopenia (HIT) is a potentially

61 Heparin-induced thrombocytopenia (HIT) is a prothromboti

62 Heparin-induced thrombocytopenia (HIT) is a prothromboti

63 Heparin-induced thrombocytopenia (HIT) is a relatively c

64 Heparin-induced thrombocytopenia (HIT) is a significant

65 Heparin-induced thrombocytopenia (HIT) is a thrombotic c

66 Heparin-induced thrombocytopenia (HIT) is an adverse dru

67 Heparin-induced thrombocytopenia (HIT) is an antibody-me

68 Heparin-induced thrombocytopenia (HIT) is an autoimmune

69 Heparin-induced thrombocytopenia (HIT) is an immune comp

70 Heparin-induced thrombocytopenia (HIT) is an immune-medi

71 Heparin-induced thrombocytopenia (HIT) is an immune-medi

72 Heparin-induced thrombocytopenia (HIT) is an immune-medi

73 Heparin-induced thrombocytopenia (HIT) is an important,

74 Heparin-induced thrombocytopenia (HIT) is caused by anti

75 Heparin-induced thrombocytopenia (HIT) is characterized

76 Heparin-induced thrombocytopenia (HIT) is due primarily

77 Rapid laboratory assessment of heparin-induced thrombocytopenia (HIT) is important for

78 Rapid exclusion of heparin-induced thrombocytopenia (HIT) is needed to dete

79 ies of thrombocytopenia in critical illness, heparin-induced thrombocytopenia (HIT) is one potential

80 Life-threatening heparin-induced thrombocytopenia (HIT) is treated with t

81 Current guidelines for heparin-induced thrombocytopenia (HIT) management recomm

82 Monoclonal Abs against PF4 and IgG from a heparin-induced thrombocytopenia (HIT) patient were appl

83 Patients with heparin-induced thrombocytopenia (HIT) remain at risk fo

84 The diagnosis of heparin-induced thrombocytopenia (HIT) requires detectio

85 The existence of spontaneous heparin-induced thrombocytopenia (HIT) syndrome (or auto

86 thrombotic thrombocytopenic purpura (TTP) or heparin-induced thrombocytopenia (HIT), and Trousseau sy

87 nheparin anticoagulants for the treatment of heparin-induced thrombocytopenia (HIT), few data are ava

88 abel treatments(rivaroxaban, dabigatran) for heparin-induced thrombocytopenia (HIT),and also outline

89 ggesting that NA-PF4 can potentially cause a heparin-induced thrombocytopenia (HIT)-like prothromboti

90 the diagnostic accuracy of immunoassays for heparin-induced thrombocytopenia (HIT).

91 the antibody-mediated adverse drug effect of heparin-induced thrombocytopenia (HIT).

92 ntibodies are central to the pathogenesis of heparin-induced thrombocytopenia (HIT).

93 icoagulant that can cause a condition called heparin-induced thrombocytopenia (HIT).

94 ACs) are attractive options for treatment of heparin-induced thrombocytopenia (HIT).

95 most frequent drug-induced immune disorder, heparin-induced thrombocytopenia (HIT).

96 4Ts is a pretest clinical scoring system for heparin-induced thrombocytopenia (HIT).

97 g to the prothrombotic adverse drug reaction heparin-induced thrombocytopenia (HIT).

98 ory assessment for thrombosis, bleeding, and heparin-induced thrombocytopenia [HIT]).

99 ion that occurs in a subset of patients with heparin-induced thrombocytopenia (HITT).

100 cytic leukemia; (4) do not test or treat for heparin-induced thrombocytopenia if the clinical pretest

101 in reactions in 1.80% (95% CI, 1.34%-2.37%), heparin-induced thrombocytopenia in 0%, thrombocytopenia

102 munosorbent assay should be used to identify heparin-induced thrombocytopenia in patients with multip

103 reveal a high occurrence of overdiagnosis of heparin-induced thrombocytopenia in surgical patients wi

104 Overtreatment of heparin-induced thrombocytopenia in the surgical ICU con

105 Heparin-induced thrombocytopenia is a common adverse eff

106 Heparin-induced thrombocytopenia is a profoundly dangero

107 Heparin-induced thrombocytopenia is a prothrombotic adve

108 Heparin-induced thrombocytopenia is a prothrombotic diso

109 Delayed-onset heparin-induced thrombocytopenia is increasingly being r

110 The immune response in heparin-induced thrombocytopenia is initiated by and dir

111 penia if the clinical pretest probability of heparin-induced thrombocytopenia is low; and (5) do not

112 t count trends to guide decision to test for heparin-induced thrombocytopenia is not an optimal strat

113 hemorrhage, the state of thrombocytopenia in heparin-induced thrombocytopenia leads to an acquired hy

114 tive patients (100%) compared with 19 of 125 heparin-induced thrombocytopenia-negative patients (15%)

115 Stroke in heparin-induced thrombocytopenia occurs most often in fe

116 ften life threatening in patients undergoing heparin-induced thrombocytopenia or sepsis.

117 ation may be a result of atheroembolization, heparin-induced thrombocytopenia, or hypoperfusion.

118 There was no difference in mortality between heparin-induced thrombocytopenia positive and negative p

119 Heparin-induced thrombocytopenia positive patients were

120 orbent assay; 10 patients were identified as heparin-induced thrombocytopenia positive.

121 troban, lepirudin, or fondaparinux: 10 of 10 heparin-induced thrombocytopenia-positive patients (100%

122 Heparin-induced thrombocytopenia-positive patients were

123 severe thrombocytopenia, and within 2 wks of heparin-induced thrombocytopenia presentation.

124 Heparin-induced thrombocytopenia presents 5 to 12 days a

125 ence of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia related thrombosis, 8.3

126 ence of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia-related thrombosis amon

127 The optimal criteria for diagnosis of heparin-induced thrombocytopenia remain unclear, contrib

128 Heparin-induced thrombocytopenia represents a unique cli

129 Heparin-induced thrombocytopenia requires alternative an

130 omplexes (ICs) mediate inflammation, such as heparin-induced thrombocytopenia, rheumatoid arthritis,

131 comprehensive review, the authors highlight heparin-induced thrombocytopenia's risk factors, clinica

132 Heparin-induced thrombocytopenia testing results and pla

133 tional algorithm to interpret the results of heparin-induced thrombocytopenia testing.

134 Antibodies associated with heparin-induced thrombocytopenia/ thrombosis (HITT) are

135 be demonstrated in almost all patients with heparin-induced thrombocytopenia/thrombosis (HIT/HITT) a

136 Heparin-induced thrombocytopenia/thrombosis (HIT/HITT) i

137 Heparin-induced thrombocytopenia/thrombosis (HIT/T) is a

138 Heparin-induced thrombocytopenia/thrombosis (HIT/T) is t

139 peutic effect and can also cause thrombosis (heparin-induced thrombocytopenia/thrombosis syndrome).

140 ications for TPE for cardiac surgery include heparin-induced thrombocytopenia, thrombotic thrombocyto

141 itted to surgical ICUs and were suspected of heparin-induced thrombocytopenia to identify how often p

142 etrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II; NCT01304238).

143 lateral adrenal hemorrhage in the setting of heparin-induced thrombocytopenia uniformly presenting wi

144 a, WI) enzyme-linked immunosorbent assay for heparin-induced thrombocytopenia using the carbon-14 ser

145 isastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hos

146 eir niche for the treatment of patients with heparin-induced thrombocytopenia, whereas bivalirudin is

147 Heparin-induced thrombocytopenia with thrombosis (HITT)

148 ew stroke and stroke-associated mortality in heparin-induced thrombocytopenia without increasing intr

149 roves clinical outcomes in patients who have heparin-induced thrombocytopenia, without increasing ble